Therapeutic Implications and Prognostic Significance of c-Met in Esophageal Squamous Cell Cancer Ching Tzao 1, Chun-Ya Wang 1, Ban-Hen Chen 1, Guang-Huan.

Slides:

Advertisements

Similar presentations

Carcinogenesis Stages & Mechanisms. Eva Szabo & Gail L. Shaw

Advertisements

Cancer Genetics Is Cancer a Genetic Disease? Cancer is not a classic genetic disease, instead, Genetic background (set-up) has a definite role in cancer.

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

AT 4 Receptor Ligands as Angiogenic, Anti-angiogenic, and Anti-cancer Agents How do you translate basic science into a clinically useful technology?

MDM2: Oncogene Chan Lee. Discovery of MDM2: starting with tumor suppressor p53.

Characterization of a potential new drug in cancer therapy Lab 2 Salah Farag.

HOXC6 and HOXC8 are potentially novel prognosis predictors of esophageal squamous cell carcinoma Keneng Chen, M.D., PhD, RCSF Luyan Shen, M.D., PhD 2015/4/28.

Fundeni Centre for Immunogenetics & Virology

Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness Gary Xiao, Ph.D. Professor and Director School of Pharmaceutical Science & Technology.

Investigating the genetic instability and expression of four DNA repair related proteins in the peripheral lymphocytes of 36 untreated lung cancer patients.

E2F3 in Soft Tissue Sarcoma Development M. Scurr; A Feber; J Shipley; A Fletcher; N Dennis; I Judson; C Cooper.

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Changes in Tumor Growth and Metastatic Capacities of J82 Human Bladder Cancer Cells Suppressed by Down-regulation of Calreticulin Expression Speaker: Yi-Chien.

The c-Met receptor contributes to motility and invasion in high grade STS; a potential therapeutic target Sarah E. Myers, Theresa G. Nguyen, Quan-Sheng.

12 th Annual CTOS Meeting 2006 SESSION 11 Molecular biology for the patients: Define new targets? Predict Outcome? Moderators: Ole Steen Nielsen & Irene.

Kyoto University, Japan

SC121 Unit Three Karma Pace, MS AIM: kpacemcduffy.

Isosteviol derivatives induced apoptosis in Human lung cancer via targeting MEK/MAPK pathway: An in vitro and in vivo study Ahmed M Malki 1,,PhD Stephen.

INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,

SP Cancer Metastasis Summary Hypothesis: We hypothesize that miRNAs regulate breast cancer cell invasiveness and metastasis by synergistically targeting.

Potential therapeutic target & predictive biomarker Oncogenic IGFBP2 Sonya Song ( 宋韦 ) Beijing Shijitan Hospital Department of Oncology The Capital Medical.

Fibroblast growth factor receptor (FGFR) gene family aberrations in cholangiocarcinoma Katsuyuki Miyabe, MD, PhD Lewis R. Roberts, MB ChB, PhD.

EXPRESSION OF HER-2 CORRELATED PROTEINS IN ILEAL CARCINOIDS Azzoni C., Giordano G., Bottarelli L., Tamburini E., D’Adda T., Pizzi S., Rindi G., Bordi C.

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Layla Barkal and Jessica Perez

Tyrosine Kinases as Targets for Cancer Therapy Krause DS, Van Etten RA N Engl J Med 2005;353(2): Krause DS, Van Etten RA N Engl J Med 2005;353(2):

Dr. Hiba Wazeer Al Zou’bi

Relationship Between STAT3 Inhibition and the Presence of p53 on Cyclin D1 Gene Expression in Human Breast Cancer Cell Lines Introduction STAT3 and p53.

Fat and Breast Cancer Mei-Chun Chen, MD 1,2 ; Hsu Ma, PhD 1 Taipei Veterans General Hospital, Taiwan 1.Division of Plastic and Reconstructive Surgery,

Dual Inhibition of Cdc7 and Cdk9 by PHA Suppresses Hepatocarcinoma Synergistically with 5-FU Xi Chen, MD, PhD Associate Professor, Zhejiang University.

Targeting of reactive oxygen species can be a potential therapeutic strategy for cancer treatment Ying-Ray Lee 1, San-Yuan Chen 2, and Hau-Ren Chen 3 1.

EUKARYOTIC CELL SIGNALING VII Abnormal Signaling in Cancer Signaling to p53 Dr. Ke Shuai Office: 9-240M Factor Tel: X69168

The role of regulatory B cells on hepatocellular carcinoma progression Conclusion Results Fig2. (A and B) In vivo, Bregs in SCID mice increased the size.

第三章 Survivin siRNA nano particles are capable of inhibiting liver cancer cell growth both in vitro and in vivo Suoqin Tang,MD, Kuiyao Qu,MD, Yi Zhang,MD.

Prof. Jae Heon, Jeong/R2 Cheol Hyun, Lee J of Clinical oncology, Vol 31 Number 4, Feb.1, 2013.

Samsung Genome Institute Samsung Medical Center

Leila Kokabee*, Xianhui Wang, Cheryl Eifert, Douglas S. Conklin

Cell Physiol Biochem 2017;42:2582– DOI: /

Companion PowerPoint slide set Obesity-associated breast cancer risk: a role for epigenetics? This teacher slide set was created by Dana Haine, MS, of.

Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models Xavier CP, Pesic M, Vasconcelos MH. Curr Cancer Drug.

Mouse Double Minute 2 (MDM2)

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker Chun-Yi.

MicroRNA-101 Inhibits Growth, Proliferation and Migration and Induces Apoptosis of Breast Cancer Cells by Targeting Sex-Determining Region Y-Box 2 Cell.

Drug concentration (μM)

Molecular Therapy - Oncolytics

Keneng Chen, M.D., PhD, RCSF Luyan Shen, M.D., PhD 2015/4/28

Table 1. Scientific findings of previously published work on Graviola

Taipei Veterans General Hospital,

NSAIDs and esophageal cancer

The Kinase-Independent, Second Life of CDK6 in Transcription

Figure 1 Cellular processes involved in cancer development

Regulating the Cell Cycle

Volume 114, Issue 2, Pages (February 1998)

Dan Gordon Gastroenterology Volume 114, Issue 4, (April 1998)

NSAIDs and esophageal cancer

Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling.

Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase.

Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis

Deregulated p21WAF1 Overexpression Impacts Survival of Surgically Resected Esophageal Squamous Cell Carcinoma Patients Yih-Gang Goan, MD, Hon-Ki Hsu,

10.3 Regulating the Cell Cycle

Poster session n. 2.

Yu-Fen Wang1, Ya-Chi Chan1, Dar-Ren Chen1, 2, Hui-Yi Lin3

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Oncogenic ALK signaling.

Canonical gliomagenesis mediators EGFR, P53, and retinoblastoma protein (RB1) are important for cancer signaling. Canonical gliomagenesis mediators EGFR,

Molecular Therapy - Oncolytics

Antitumor effects of celastrol in vitro and in vivo.

The Role of TIPE2 Protein in Invasive Breast Carcinoma

Targeting GAPLINC decreased CD44 expression and tumor growth in vivo.

Presentation transcript:

Therapeutic Implications and Prognostic Significance of c-Met in Esophageal Squamous Cell Cancer Ching Tzao 1, Chun-Ya Wang 1, Ban-Hen Chen 1, Guang-Huan Sun 2 Division of Thoracic Surgery 1, Department of Surgery Taipei Medical University Hospital, Taipei Medical University Department of Surgery 2, Tri-Service General Hospital Taipei, Taiwan

No Disclosures

Introduction c-Met: a sub-family of RTKs with high-affinity to its ligand hepatocyte growth factor (HGF). (Naldini et al, 1991) Important in regulation of cell migration, invasion, cell proliferation and angiogenesis. (Sonnenberg et al, 1993) Activated by overexpression and constitutive kinase activation by HGF, gene amplification and its mutation (Christensen et al, 2005) Involved in carcinogenesis and tumor progression and a potential target for cancer therapy, most studied in lung, colon and breast cancers. (Ma et al., 2007)

Aims To determine prognostic significance of c- Met in esophageal squamous cancer (ESCC). To investigate if c-Met exerts anticancer effects in ESCC cells in vitro and in vivo.

Materials and Methods Immunohistochemistry for c-Met expression in 97 resected ESCC tumor samples KYSE-170 & KYSE-510 ESCC cell lines Drugs: c-Met inhibitors (SU11274 and PHA665752) Cell viability by cytotoxicity (MTT) assay Cell cycle analysis by FACS Cell migration assay Immunoblotting & immunofluorescence staining Tumor xenograft in response to c-Met inhibitor

Results

Cytotoxicity (MTT) assay by c-Met inhibitors

c-Met inhibitors Induced Cell Cycle Arrest in ESCC Cells Control 24hr48hr KYSE-510 G1: 67.9 ±0.5% G2: ±0.66% S: 7.84 ±0.54% G1: 59.9 ±0.78% G2: ±0.93% S: 8.9 ±0.51% G1: ±0.78% G2: ±0.56% S: 7.84 ±0.3% KYSE-170 G1: ±0.33% G2: 16.6 ±0.34% S: ±0.24% G1: ±0.33% G2: ±0.36% S: 5.14 ±0.13% G1: ±0.15% G2: ±0.23% S: 5.41 ±0.16%

Alterations of Cell Cycle Regulatory Proteins Induced by c-Met Inhibitors

Intrinsic Apoptosis Induced by c-Met Inhibitors in ESCC Cells KYSE-170 ESCC cell line

Control-naïve HGF HGF+SU  M HGF+SU  M HGF+PHA  M HGF+PHA  M * * * * KYSE-170

Control-naïve HGF HGF+SU  M HGF+SU  M HGF+PHA  M HGF+PHA  M KYSE-510

c-Met inhibitors retarded growth of KYSE-170 tumors SU treatment PHA treatment

Conclusions c-Met expression may serve as an independent prognostic predictor for ESCC. c-Met inhibitors, SU11274 and PHA exerted significant anticancer effects in ESCC cell lines in vitro and in vivo, suggesting that c-Met may serve as a potential therapeutic target for ESCC.

Acknowledgments Dr. Yutaka Shimada from University of Kyoto, Japan for his kind gift of KYSE ESCC cell lines A grant support from National Science Council, Taiwan, Republic of China. (NSC B )